<DOC>
	<DOCNO>NCT00354224</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine oxaliplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give capecitabine together oxaliplatin work treat patient locally advance , unresectable , metastatic stomach cancer .</brief_summary>
	<brief_title>Capecitabine Oxaliplatin Treating Patients With Locally Advanced , Unresectable , Metastatic Stomach Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response proportion patient locally advance , unresectable , metastatic gastric cancer treat capecitabine oxaliplatin . Secondary - Determine tolerability toxicity regimen patient . - Determine median progression-free survival patient treat regimen . OUTLINE : This open-label study . Patients receive oxaliplatin IV 2 hour day 1 oral capecitabine twice daily day 1-7 . Treatment repeat every 14 day absence unacceptable toxicity disease progression . After completion study treatment , patient follow every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 46 patient accrue study .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm gastric cancer Locally advance , unresectable , metastatic disease Measurable disease , define least 1 lesion accurately measure ≥ 1 dimension ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan No known brain metastasis PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 Karnofsky PS 60100 % WBC ≥ 3,000/mm³ Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin normal AST/ALT ≤ 2.5 time upper limit normal Creatinine ≤ 1.5 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception study 6 month completion study treatment Able swallow No history allergic reaction attribute compound similar chemical biologic composition fluoropyrimidines platinum chemotherapy agent No uncontrolled intercurrent illness include , limited following : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would preclude study compliance PRIOR CONCURRENT THERAPY : More 4 week since prior chemotherapy radiotherapy ( 6 week nitrosoureas mitomycin C ) recover At least 6 month since prior radiotherapy capecitabine radioenhancer No concurrent combination antiretroviral therapy HIVpositive patient No concurrent chemotherapy No concurrent palliative radiotherapy No concurrent hormonal therapy except follow : Steroids adrenal failure Hormones nondisease related condition ( e.g. , insulin diabetes ) Intermittent use dexamethasone antiemetic No concurrent investigational agent No concurrent anticancer agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
</DOC>